Gilead Sciences extended the expiration of its tender offer for all outstanding shares of Arcellx, Inc., setting a new deadline of April 24 2026 at 5:00 p.m. Eastern Time. The offer remains $115.00 in cash per share, net to the seller, and includes a contingent value right that entitles holders to a $5.00 cash payment per right if cumulative global net sales of Arcellx’s lead product anito‑cel reach at least $6.0 billion by December 31 2029, with the payment due on March 31 2030.
Only about 7.5 % of Arcellx’s shares—roughly 4,389,763 shares—had been tendered as of March 31 2026. The low participation rate prompted Gilead to grant shareholders additional time to evaluate the offer, a common practice when a tender offer has not yet achieved the threshold needed to trigger a merger. The extension reflects both the need for more shareholder approval and the strategic importance Gilead places on securing Arcellx’s assets.
The announced equity value of the transaction is approximately $7.8 billion, though some reports cite a $4.9 billion figure. The discrepancy stems from differing interpretations of the offer’s implied value versus the cash component alone. Gilead’s public statements emphasize the $7.8 billion figure, aligning with the full equity value of the tender offer.
Arcellx’s D‑Domain CAR‑T platform, particularly its BCMA‑directed candidate anito‑cel, is a key driver of the deal. The platform’s novel D‑Domain technology offers enhanced specificity and binding affinity, positioning it as a potential cornerstone of Gilead’s oncology and in‑vivo cell therapy strategy. Gilead’s CEO Daniel O’Day highlighted the conviction that anito‑cel could become a foundational treatment for multiple myeloma and that the D‑Domain binder would support broader in‑vivo cell therapy ambitions in oncology and inflammation.
Rami Elghandour, Arcellx’s CEO, praised Gilead as a “world‑class partner with the expertise to carry forward Arcellx’s legacy” and noted that Kite was well‑positioned to maximize access to anito‑cel. These statements underscore the complementary nature of the two companies’ expertise and the strategic fit of the acquisition.
The extension signals a cautious but committed approach by Gilead to expand its cell‑therapy portfolio. While the low tender participation rate introduces uncertainty about the speed of completion, the continued offer reflects Gilead’s belief in the long‑term value of Arcellx’s technology and its alignment with the company’s broader oncology strategy.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.